SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-22-001788
Filing Date
2022-12-27
Accepted
2022-12-27 07:00:14
Documents
13
Period of Report
2022-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALDEYRA THERAPEUTICS, INC. 8-K a53133738.htm   iXBRL 8-K 45775
2 EXHIBIT 10.2 a53133738ex10_2.htm EX-10.2 64217
  Complete submission text file 0001157523-22-001788.txt   263207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20221222.xsd EX-101.SCH 3920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20221222_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20221222_pre.xml EX-101.PRE 16040
7 EXTRACTED XBRL INSTANCE DOCUMENT a53133738_htm.xml XML 4233
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 221486786
SIC: 2834 Pharmaceutical Preparations